Blayne Welk1, Sarah Morrow2, Wendy Madarasz3, Richard Baverstock4, Jennifer Macnab5, Keith Sequeira6. 1. Division of Urology, Department of Surgery, Western University, London, Ontario, Canada. Electronic address: blayne.welk@sjhc.london.on.ca. 2. Department of Clinical Neurosciences, Western University, London, Ontario, Canada. 3. St. Joseph's Health Care, London, Ontario, Canada. 4. Vesia (Alberta Bladder Centre), Division of Urology, Department of Surgery, University of Calgary, Calgary, Alberta, Canada. 5. Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada. 6. Department of Physical Medicine and Rehabilitation, Western University, London, Ontario, Canada.
Abstract
PURPOSE: The neurogenic bladder symptom score is a tool to measure urinary symptoms and consequences in patients with acquired or congenital neurogenic bladder. We describe score validity and reliability. MATERIALS AND METHODS: Exploratory factor analysis was used to assess item variability and subscale structure. Reliability was assessed by the Cronbach α and correlation with retest data. Validity was assessed with a priori hypotheses specifying relationships with the AUASS (American Urological Association symptom score), ICIQ-UI (International Consultation on Incontinence-Urinary Incontinence) and urinary specific quality of life SF-Qualiveen questionnaires, and a self-assessed global bladder problem score. Known groups analysis was used to further assess construct validity. RESULTS: A cohort of 230 patients with spinal cord injury (35%), multiple sclerosis (59%) and congenital neurogenic bladder (6%) were included in study. Factor analysis suggested 3 neurogenic bladder symptom score domains, including incontinence, storage and voiding symptoms, and consequences. Overall internal consistency was high (Cronbach α=0.89). Test-rest reliability was also excellent with an ICC2,1 of 0.91. Validity was demonstrated by the confirmation of hypothesized correlations with the AUASS, ICIQ-UI and SF-Qualiveen, and significant differences in neurogenic bladder symptom score scores among known groups. Patients with a history of seeing a urologist had a significantly higher mean score, as did those with a higher global bladder problem score (22.1 vs 17.1 and 22.1 vs 12.6, respectively, each p<0.001). CONCLUSIONS: The neurogenic bladder symptom score, developed specifically to assess symptoms and consequences associated with neurogenic bladder dysfunction, has appropriate psychometric properties. Depending on the measurement need individual domains may be selected or it can be used as a comprehensive score.
PURPOSE: The neurogenic bladder symptom score is a tool to measure urinary symptoms and consequences in patients with acquired or congenital neurogenic bladder. We describe score validity and reliability. MATERIALS AND METHODS: Exploratory factor analysis was used to assess item variability and subscale structure. Reliability was assessed by the Cronbach α and correlation with retest data. Validity was assessed with a priori hypotheses specifying relationships with the AUASS (American Urological Association symptom score), ICIQ-UI (International Consultation on Incontinence-Urinary Incontinence) and urinary specific quality of life SF-Qualiveen questionnaires, and a self-assessed global bladder problem score. Known groups analysis was used to further assess construct validity. RESULTS: A cohort of 230 patients with spinal cord injury (35%), multiple sclerosis (59%) and congenital neurogenic bladder (6%) were included in study. Factor analysis suggested 3 neurogenic bladder symptom score domains, including incontinence, storage and voiding symptoms, and consequences. Overall internal consistency was high (Cronbach α=0.89). Test-rest reliability was also excellent with an ICC2,1 of 0.91. Validity was demonstrated by the confirmation of hypothesized correlations with the AUASS, ICIQ-UI and SF-Qualiveen, and significant differences in neurogenic bladder symptom score scores among known groups. Patients with a history of seeing a urologist had a significantly higher mean score, as did those with a higher global bladder problem score (22.1 vs 17.1 and 22.1 vs 12.6, respectively, each p<0.001). CONCLUSIONS: The neurogenic bladder symptom score, developed specifically to assess symptoms and consequences associated with neurogenic bladder dysfunction, has appropriate psychometric properties. Depending on the measurement need individual domains may be selected or it can be used as a comprehensive score.
Authors: Blayne Welk; Sara Lenherr; Sean Elliott; John Stoffel; Angela P Presson; Chong Zhang; Jeremy B Myers Journal: Spinal Cord Date: 2017-11-29 Impact factor: 2.772
Authors: Denise G Tate; Tracey Wheeler; Giulia I Lane; Martin Forchheimer; Kim D Anderson; Fin Biering-Sorensen; Anne P Cameron; Bruno Gallo Santacruz; Lyn B Jakeman; Michael J Kennelly; Steve Kirshblum; Andrei Krassioukov; Klaus Krogh; M J Mulcahey; Vanessa K Noonan; Gianna M Rodriguez; Ann M Spungen; David Tulsky; Marcel W Post Journal: J Spinal Cord Med Date: 2020-03 Impact factor: 1.985
Authors: A Ghezzi; E Mutta; F Bianchi; S Bonavita; F Buttari; A Caramma; R Cavarretta; D Centonze; G C Coghe; G Coniglio; U Del Carro; M T Ferrò; M G Marrosu; F Patti; M Rovaris; M Sparaco; I Simone; C Tortorella; R Bergamaschi Journal: Neurol Sci Date: 2015-11-27 Impact factor: 3.307